Management of hepatocellular carcinoma on the waiting list before liver transplantation: Time for controlled trials?

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

BACKGROUND Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor. AIMS To assess the cost effectiveness of adjuvant therapy while waiting for liver transplantation in HCC patients. METHOD Using a Markov model, a hypothetical cohort of cirrhotic patients with early HCC was considered for: (1) adjuvan...

LIVER AND BILIARY DISEASE Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Background: Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor. Aims: To assess the cost effectiveness of adjuvant therapy while waiting for liver transplantation in HCC patients. Method: Using a Markov model, a hypothetical cohort of cirrhotic patients with early HCC was considered for: (1) adjuvant...

Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma.

BACKGROUND/OBJECTIVES The study evaluates the outcome of patients who performed orthotopic liver transplantation (LT) as treatment for hepatocellular carcinoma (HCC), with percutaneous ethanol injection (PEI) while on the waiting list, verifying the effectiveness of this treatment in producing tumor necrosis and avoiding dropout and identifying treatment-related complications. MATERIAL AND ME...

Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma

Liver transplantation for hepatocellular carcinoma.

Liver transplantation has become the best option in patients with decompensated cirrhosis and a small hepatocellular carcinoma. Indeed, because of the severity of cirrhosis, resection is usually impossible and in addition, transplantation provides survival rates close to those obtained in cirrhotic patients without malignancy (70 to 80% 3-year survival rate). In patients with a small hepatocell...